---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-040946"
form_type: "8-K"
ticker: "LRMR"
cik: "0001374690"
company_name: "Larimar Therapeutics, Inc."
filed_at: "2023-08-10T23:59:59+00:00"
generated_at: "2026-06-11T16:56:16.854567+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Larimar Therapeutics Q2 net loss $8.4M; FDA clears 50 mg cohort and OLE trial for CTI-1601 in FA

## Summary
- Net loss of $8.4M (-$0.19/share) vs $8.7M in Q2 2022; cash $104.2M, runway into Q4 2024.
- FDA cleared initiation of 50 mg cohort in Phase 2 FA trial and Open-Label Extension after review of 25 mg data.
- Top-line data from 25 mg cohort showed CTI-1601 was well-tolerated and increased frataxin levels from baseline.
- New CMO appointed: Russell Clayton, DO, replaces retired Nancy Ruiz.
- Expect top-line 50 mg data in 1H 2024; OLE interim data in Q4 2024.

## SEC filing metadata
- accession: 0000950170-23-040946
- form_type: 8-K
- ticker: LRMR
- cik: 0001374690
- company_name: Larimar Therapeutics, Inc.
- filed_at: 2023-08-10T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1374690/000095017023040946/0000950170-23-040946-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1374690/000095017023040946/lrmr-20230810.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-040946
- JSON: https://secwatch.observer/filing/0000950170-23-040946.json
- Plain text: https://secwatch.observer/filing/0000950170-23-040946.txt

## Key facts
- Earnings Releases
  Larimar Therapeutics, Inc. reported the second quarter ended June 30, 2023 results: net income $8.4 million, or $0.19 per share, EPS $0.19 per share.
  - Period: the second quarter ended June 30, 2023
  - Net income: $8.4 million, or $0.19 per share
  - EPS: $0.19 per share
  - Result: reported results
  source text: The Company reported a net loss for the second quarter of 2023 of $8.4 million, or $0.19 per share, compared to a net loss of $8.7 million, or $0.47 per share, for the second quarter of 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1374690/000095017023040946/0000950170-23-040946-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.